Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects

Journal of Clinical Pharmacology

Volumn 39, Issue 3, 1999, Pages 281-288

  Wong, Y Nancy ^a,b   King, S Peter ^a   Simcoe, Donna ^a   Gorman, Steve ^a   Laughton, Watson ^a   McCormick, George C ^a   Grebow, Peter ^a  

^a CEPHALON INC   (United States)

^b EISAI RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; MODAFINIL; MODAFINIL ACID; MODAFINIL SULFONE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG URINE LEVEL; ENANTIOMER; FEMALE; FEVER; HEADACHE; HUMAN; MALE; METABOLITE; NARCOLEPSY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PULSE RATE; SEX DIFFERENCE; STEREOSPECIFICITY;

ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; FEVER; HEADACHE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHARYNGITIS; SEX FACTORS; TABLETS;

EID: 0032979760     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fuxe K, Rambert FA, Ferraro L, O'Connor W, Laurent PH, Agnati LF, Tanganelli S: Preclinical studies with modafinil. Evidence for vigilance enhancement and neuroprotection. Drugs of Today 1996;32:313-326.
2. Lagarde DPS, Anton G: Comparative study of stimulant effects of d-amphetamine sulfate and modafinil, an original psychostimulant. Eur J Pharmacol 1990;183:1476.
3. Duteil J, Rambert FA, Pessonier J, Hermant JF, Gombert R: Central alpha-adrenergic stimulation in relation to the behavior stimulating effect of modafinil: studies with experimental animals. Eur J Pharmacol 1990;180:49-58.
4. Lin J, Hou Y, Jouvet M: Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immonochemistry in the cat. Neurobiology 1996;93:14128-14133.
5. Moachon G, Kanmacher I, Clenet M, Matinier D: Pharmacokinetic profile of modafinil. Drugs of Today 1996;32:327-337.
6. Billard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill SS, Lubin S: Modafinil: a double-blind multicenter study. Sleep 1994;8(Suppl.):107-112.
7. Besset A, Tafti M, Villemin E, Billiard M: Effects of modafinil (300 mg) on sleep, somnolence, and alertness of narcoleptic patients. Neurophysiologie Clinique 1996;23:47-60.
8. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S: Effects of modafinil on symptomatology of human narcolepsy. Clinical Neuropharmacology 1993;16(1):46-53.
9. US Modafinil in Narcolepsy Study Group: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
10. Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC, Grebow PE: A double-blind, placebo-controlled, ascending-dose evaluation the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol (in press).
11. Gorman SH: A reverse-phase HPLC assay for the determination of d- and l-modafinil in human plasma. Pharm Res 1995;12:S-22.
12. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
13. Pharm-NCA Non-Compartmental Pharmacokinetic Data Analysis Software, Version 1.3c. Créteil, France: SIMED S.A., 1994.
14. Pharm-ABS Drug Absorption Rate Data Analysis Software, Version 1.31b. Créteil, France: SIMED S.A., 1994.
15. Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
16. Laffont F: Clinical assessment of modafinil. Drugs of Today 1996;32:339-347.
17. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE: Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination to healthy male volunteers. J Clin Pharmacol 1998;38:276-282.
18. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50(2):222-239.
19. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, Fishman K, Guzelian PS, Voorhees JJ: Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;53:265-273.
20. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
21. Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Ahoe NW, Andrea R: Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther 1975;18:425-432.
22. Shock NW: Age changes in physiological functions in the total animals: the role of tissue loss. In, Strehler BL (ed.): The Biology of Aging. Washington, DC: American Institute of Biological Sciences, 1960;250-264.